A Phase 1/2 Open-label Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214 Nivolumab and Ipilimumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
Study Overview
The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of the study drug (NKTR-214) given together with Opdivo?.
Study Description
The purpose of this study is to study the safety, tolerability, and effectiveness of the study drug (NKTR-214) given together with Opdivo.
Additional Information:
Participants will be compensated for their participation.
Research Study Identifier: TX7957
ClinicalTrials.gov Identifier: NCT1705311414 (NKTR16-214-02)
Principal Investigator:
Roberto Pili, MD
Currently Recruiting